Keros Therapeutics, Inc. (KROS)
Nasdaq: KROS · Pharmaceutical Preparations · Lexington, MA · filing with the SEC since 2016
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Mar 4, 2026 | Feb 26, 2025 | Feb 28, 2024 | Mar 3, 2023 | Mar 9, 2022 | Mar 25, 2021 | · |
| Revenue | 244,061 | 3,550 | 151 | 0 | 20,100 | 0 | 10,000 |
| Research and development | 129,643 | 173,629 | 135,258 | 87,265 | 55,143 | 33,860 | 17,379 |
| General and administrative | 46,849 | 40,754 | 34,834 | 27,525 | 21,330 | 12,797 | 3,184 |
| Total operating expenses | 176,492 | 214,383 | 170,092 | 114,790 | 76,473 | 46,657 | 20,563 |
| Operating income | 67,569 | -210,833 | -169,941 | -114,790 | -56,373 | -46,657 | -10,563 |
| Interest expense | · | 0 | 0 | 1 | 4 | 6 | · |
| Interest income (expense), net | · | · | · | · | · | -6 | -8 |
| Other income (expense), net | -539 | -954 | -206 | -613r | -383r | 160 | 241 |
| Total non-operating income (expense) | 24,328 | 23,780 | 16,949 | 10,111 | -360 | 1,124 | -1,773 |
| Income before income taxes | 91,897 | -187,053 | -152,992 | -104,679 | -56,733 | -45,533 | -12,336 |
| Income tax expense | 4,883 | 300 | 0 | 0 | 2,011 | -172 | 0 |
| Net income | 87,014 | -187,353 | -152,992 | -104,679 | -58,744 | -45,361 | -12,336 |
| Preferred dividends | · | · | · | · | · | 0 | 1,800 |
| Net income to common shareholders | 87,014 | -187,353 | -152,992 | -104,679 | -58,744 | -45,361 | -14,136 |
| Earnings per share, basic | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | · |
| Earnings per share, diluted | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -2.93 | -6.08 |
| Weighted average shares, basic | 37,221,211 | 37,437,652 | 29,447,119 | 25,241,030 | 23,333,914 | 15,506,397 | · |
| Weighted average shares, diluted | 37,859,106 | 37,437,652 | 29,447,119 | 25,241,030 | 23,333,914 | 15,506,397 | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 15,506,397 | 2,326,857 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseDebtInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossPreferred dividends paid to preferred holders before common shareholders
us-gaap:PreferredStockDividendsIncomeStatementImpactNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted